Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

Inclusion Criteria:

* Patient between 18 and 60 years old (less than 61 years old)
* With newly diagnosed with AML according to WHO classification:
* With 20% or more blasts in the bone marrow
* Patients with history of tumors other than myeloproliferative disorders or myelodysplastic syndromes, having received chemotherapy and/or radiotherapy without previous history of myelodysplastic syndromes are eligible for the present study
* High-risk cytogenetics defined as one the following abnormalities : 5/5q-, 7/7q-, t(6,9), 11q23 abnormality excluding t(9;11), 3q abnormality,complex karyotype (\>3 abnormalites)
* Left ventricular ejection fraction (LVEF) \> 50% on echocardiography or multigated acquisition (MUGA) scan or similar radionuclide angiographic scan.
* Adequate liver function (all of the following) except if secondary to the leukemia:

Total bilirubin below 1.5 x upper limit of normal (ULN), AST and ALT below 2.5 x ULN , gamma-GT below 2.5 x ULN,

* Adequate kidney function (all of the following): Serum creatinine below 1.5 x ULN, Creatinine clearance above 50 mL/min (Cockroft and Gault formula)
* ECOG performance status \< or = 2.
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
* The patient must give written (personally signed and dated) informed consent before completing any study-related procedure which means assessment or evaluation that would not form part of the normal medical care of the patient.
* Affiliated to the French Social Security (Health Insurance).

Exclusion Criteria:

* Previous allogeneic stem cell transplantation.
* Pre-existing aplastic anemia
* Presence of favourable cytogenetics with t(8;21), t(15;17), or inv(16)
* Previous history of MDS or myeloproliferative neoplasm
* Uncontrolled active infection.
* History of arrythmia.
* Cardiac toxicity induced by another anthracycline administration
* Maximum cumulative dose reached for any anthracyclin
* Allergy to cytarabine, daunorubicin, fish or egg proteins10. Significant neurologic (grade \> 2) or psychiatric disorder, dementia or seizures.
* Clinical symptoms suggesting active central nervous system leukemia.
* Degenerative or toxic encephalopathy
* Severe complications of leukemia such as:Uncontrolled bleeding, Pneumonia with hypoxia or shock
* Prior total body irradiation \> 10 Gy.
* Known active HIV, Hepatitis B or C infection
* Pregnancy or breastfeeding
* Concomitant anti-amarile vaccination (yellow fever)
* Concurrent treatment with any other anti-cancer therapy except Hydroxyurea